Amir Hasan

Happy birthday to the woman who lights up every room she walks into. I love you, Miche.

@ultromics @tabrahammd @DrRossUpton @AmirHasan__ @tala_bynum Our thanks to @ultromics for partnering with @ASE360

This will be a great session- come!

Featured in @AuntMinnie: Ultromics raises $55M in funding round auntminnie.com/clinical-news/…

This funding will accelerate our mission to make AI diagnostics standard of care for heart failure — and help millions of patients receive earlier, life-changing treatment. Thank you to our incredible team, our partners, and everyone who has believed in the mission.

This round was co-led by @LightrockGlobal, L&G and @AllegisCapital, with continued support from @OxfordSciEnt , @GVteam (Google Ventures), BCBS Venture Fund, @UniofOxford , and leading U.S. health systems like @UChicagoMed and @UPMCEnterprises

This is a direct result of years of relentless dedication to research, product development, clinical validation, clinical implementation and belief that AI can transform the outcomes of patients suffering from heart failure.

🚨From 0 to C - I’m proud to share @ultromics has raised a $55M Series C!🚨 ultromics.com/press-releases…

Today marks a historic milestone for Ultromics: we’ve raised $55M in Series C funding! ultromics.com/press-releases… Co-led by Lightrock, L&G, and Allegis Capital, with support from Oxford Science Enterprises, GV, Blue Venture Fund, Oxford University, UChicago Medicine Ventures, and UPMC Enterprises. We are proud to continue our mission to transform heart disease detection and help drive earlier diagnosis through AI.

Ultromics just returned from #CVI2025 in Texas! It was great to connect with attendees, customers, and fellow innovators in cardiovascular imaging. Thanks to @cvinnovations for having us, and to everyone who stopped by to chat. We’re excited for what’s ahead! #Cardiology #CVI

Our #EHJ study is making headlines! We’re proud to see @Medscape feature our research on using AI to detect cardiac amyloidosis. EchoGo® Amyloidosis is FDA-cleared and can identify cardiac amyloidosis from a single routine echo view: medscape.com/viewarticle/ai… #Cardiology #EchoGo

@ultromics Congratulations @AkhilNarangMD and team. Really elegant study!

New multi-center validation in #JACCAdvances compared multiple algorithms for detecting Cardiac #Amyloidosis. EchoGo® Amyloidosis demonstrated the highest sensitivity and accuracy (AUC 0.92). See paper: sciencedirect.com/science/articl… The study highlights the growing role of AI in enabling earlier and supporting detection, and shows AI outperforming traditional EHR and rules-based methods #CardioEd #CardioTwitter #EchoFirst

AI-enhanced echocardiography improves early detection of amyloid buildup in the heart. newsnetwork.mayoclinic.org/discussion/ai-… An artificial intelligence (AI) model developed by Mayo Clinicand Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for cardiac amyloidosis, a rare and progressive type of heart failure, according to a new study. The model is the first and only AI tool of its kind. #amyloidosis #MedTwitter #MedEd #cardiacamyloidosis

Exciting to see a new study examining this @US_FDA cleared, #AI-powered, #CardiacAmyloidosis screening tool from @Ultromics. Improving rate, time to, & accuracy of diagnosis is of major importance to improving patient outcomes. Read more in the European Heart Journal:

Just published in European Heart Journal — a global milestone in AI-powered cardiac care. @UChicagoMed’s Drs. Jeremy Slivnick and Roberto Lang (in memoriam) helped lead a multi-center, international study — in collaboration with Dr. Patricia Pellikka (Mayo Clinic) and the Ultromics team — validating a first-of-its-kind AI model to improve early detection of cardiac amyloidosis using echocardiography. The study showed that EchoGo® Amyloidosis achieved 85% sensitivity and 93% specificity — outperforming current screening tools and enabling earlier, more accurate diagnosis of this often-missed condition. “With its ability to provide fully automated detection... EchoGo® Amyloidosis offers a practical alternative that can be seamlessly integrated into routine workflows without compromising diagnostic performance.” — Dr. Jeremy Slivnick, UChicago Medicine 🔗 academic.oup.com/eurheartj/adva… #Cardiology #AIinMedicine #Amyloidosis #UChicagoMedicine #EuropeanHeartJournal

Could AI diagnose your heart disease? In a new study, an AI model outperformed current clinical scoring systems for accurately detecting and identifying cardiac amyloidosis, potentially helping doctors give patients earlier, more effective treatments. uchicagomedicine.org/forefront/rese…

Mayo Clinic and Ultromics' AI-powered echocardiography detects cardiac amyloidosis, a life-threatening heart condition, with high sensitivity and accuracy. Early detection is key. Learn more: mayocl.in/44Etbii

🚨New Publication Alert: Our Landmark Study Published in the European Heart Journal! We’re proud to share that our latest study demonstrates that EchoGo® Amyloidosis, Ultromics’ FDA-cleared AI tool, significantly improves the detection of cardiac amyloidosis using a single echocardiographic video clip. 🫀 Cardiac amyloidosis is a frequently missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, early and accurate detection is more important than ever. 💡 EchoGo® Amyloidosis is: 💙 The first FDA-cleared AI screening tool for cardiac amyloidosis 💙 Granted Breakthrough Device designation 💙 Validated in a large, multi-center, international study (n = 2,719) 💙 Highly accurate with 85% sensitivity and 93% specificity across AL, ATTRwt, and ATTRv 💙 Demonstrated superior performance vs traditional scoring systems 🌍 The study involved 18 leading global centers including Mayo Clinic, University of Chicago, Brigham and Women’s, Columbia and more. This breakthrough shows the potential for AI to help clinicians detect cardiac amyloidosis earlier, differentiate it from similar conditions like HFpEF or hypertrophic cardiomyopathy, and expand access to life-changing therapies. This is another important milestone for @ultromics as we continue to transform cardiovascular care with AI — not just through EchoGo® Amyloidosis, but also through our EchoGo® Heart Failure platform. 🔗 Full Publication: academic.oup.com/eurheartj/adva… With gratitude to our incredible collaborators: @pattypellikka @JSlivnickMD Will Hawkes @sarahcud @DocStrom @AshleyAkerman And a heartfelt tribute to the late Roberto Lang, whose leadership and vision helped make this work possible. His legacy continues through innovations like this ❤️ @ESC_Journals @escardio @ASE360 #EHJ #Echofirst #CardiacAmyloidosis #HeartFailure #AIinHealthcare #MedTech #Cardiology #DigitalHealth #EchoGo #Ultromics #Innovation #HFpEF #CardiovascularAI

Thanks for your precious help with the paper and your leadership of the international collaboration, @JSlivnickMD ! This was a dream team!